Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bagatell

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Methods (San Diego, Calif.)|August 24, 1999
Inhibition of oncogene expression using vector-generated RNA antisenseL Whitesell, X Liu, R Bagatell
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancerR Bagatell, O Khan, G Paine-Murrieta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agentsR Bagatell, G D Paine-Murrieta, C W Taylor, et al.
Bone Marrow Transplantation|May 10, 2016
Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastomaA V Desai, M B Heneghan, Y Li, et al.
Current Oncology (Toronto, Ont.)|April 26, 2014
fdg-pet in two cases of neurofibromatosis type 1 and atypical malignanciesP de Blank, K Cole, L Kersun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2010
Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumorsR Bagatell, C E Herzog, T M Trippett, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Methods (San Diego, Calif.)|August 24, 1999
Inhibition of oncogene expression using vector-generated RNA antisenseL Whitesell, X Liu, R Bagatell
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancerR Bagatell, O Khan, G Paine-Murrieta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agentsR Bagatell, G D Paine-Murrieta, C W Taylor, et al.
Bone Marrow Transplantation|May 10, 2016
Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastomaA V Desai, M B Heneghan, Y Li, et al.
Current Oncology (Toronto, Ont.)|April 26, 2014
fdg-pet in two cases of neurofibromatosis type 1 and atypical malignanciesP de Blank, K Cole, L Kersun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2010
Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumorsR Bagatell, C E Herzog, T M Trippett, et al.
Pageof 1